ismagilov Stifel has started coverage of newly public Lexeo Therapeutics (NASDAQ:LXEO) with a buy rating, saying it was bullish on…
Read More »ismagilov Stifel has started coverage of newly public Lexeo Therapeutics (NASDAQ:LXEO) with a buy rating, saying it was bullish on…
Read More »